

**Ovid Technologies, Inc.**  
**Master Subscription Agreement**

This Master Subscription Agreement (the “**Agreement**”), dated as of November 20, 2023 is between Ovid Technologies, Inc. or its applicable affiliate (pursuant to Section 11.1) (“**Ovid**” or “**Supplier**”) and Lithuanian Research Library Consortium, having offices at Saulėtekio Ave 14, LT-10223 Vilnius (“**Subscriber**” or “**LMBA**” or the “**Contracting Authority**”), and provides for Ovid to grant a subscription to Subscriber to access and use the Online Tools (as defined below), subject to the terms and conditions of this Agreement. Ovid and Subscriber are each referred to herein as a “**Party**” and collectively as the “**Parties**.”

**1. DEFINITIONS.**

- 1.1.** “**Archives**” means the specific journal archives specified in any applicable Order.
- 1.2.** “**Authorized Sites**” means the physical addresses specified in any applicable Order.
- 1.3.** “**Authorized Users**” means individual users of Subscriber who are authorized to access the Online Tools subscribed to hereunder from or through the Authorized Sites in accordance with the following, as applicable based upon Subscriber’s entity type:
- Corporate Market: (i) employees of Subscriber and (ii) independent contractors of Subscriber, each of the persons in (i) or (ii) being bound by a legal obligation to comply with this Agreement, solely to the extent such employees and independent contractors are accessing the Online Tools in accordance with the Permitted Use.
  - Academic Institution: currently enrolled students, faculty, and staff of Subscriber, and authorized walk-in users, solely to the extent such enrolled students, faculty, staff and walk-in users (while such walk-in users are physically present at the Academic Institution) are accessing the Online Tools in accordance with the Permitted Use.
  - Medical Service Provider: (i) healthcare professionals employed by Subscriber and (ii) independent contractors of Subscriber, each of the persons in (i) or (ii) being bound by a legal obligation to comply with the terms of this Agreement, solely to the extent such employees and independent contractors are accessing the Online Tools in accordance with the Permitted Use.
  - Public Library: library staff of Subscriber and walk-in patrons, solely to the extent such library staff and walk-in patrons are accessing the Online Tools while physically present at the library and in accordance with the Permitted Use.

For purposes of this Agreement, any individual users of institutions, associations or organizations (i) related or affiliated with Subscriber, or (ii) acquired by or merged with Subscriber during the term of this Agreement, will not be deemed “Authorized Users” without Ovid’s express written consent or unless expressly provided for in any applicable Order.

- 1.4.** “**Books**” means the specific editions of the electronic books specified in any applicable Order. If an Order does not specify an edition, the edition will be the current edition of the applicable electronic book as of the Order Effective Date. Books subscriber to on a Subscription Basis, unless unavailable due to an Information Provider’s terms, will include the most current edition available through Ovid. Books subscribed to on a Perpetual Access Basis only include the specific edition specified in the applicable Order.
- 1.5.** “**Databases**” means the specific electronic databases specified in any applicable Order.
- 1.6.** “**Documentation**” means any instructional materials relating to the Ovid Platform as provided in hardcopy or electronic form during the term of this Agreement.
- 1.7.** “**Effective Date**” means the date first written above.
-

- 1.8. “**Information Providers**” means content providers that have licensed to Ovid content included in one or more Online Tools.
  - 1.9. “**Journals**” means the specific electronic journals specified in any applicable Order.
  - 1.10. “**Online Tools**” means the Databases, Journals, Archives, Books and/or Other Content ordered by Subscriber pursuant to one or more Orders, designated as “Online Tools” on the applicable Order.
  - 1.11. “**Order**” means the Tender for the Services of Subscription to the Online Research Database LIPPINCOTT WILLIAMS & WILKINS JOURNALS, submitted on 12 October 2023 by Ovid and attached as Annex 1 and Annex 2 to this Agreement.
  - 1.12. “**Order Effective Date**” means the date on which the applicable Order was entered into by Ovid and Subscriber.
  - 1.13. “**Other Content**” means the Online Tools identified as “Other Content” in any applicable Order.
  - 1.14. “**Permitted Use**” means the limited purposes for which Authorized Users may use the Online Tools, specifically (i) online use of and access to the Online Tools for internal management, reference, education, research, and training purposes; (ii) using the provided “print” and “save” functionality through the Platform for limited portions of the Online Tools; (iii) for interlibrary loan (“ILL”) purposes, print data obtained from searches and transmit the printed document through Subscriber’s traditional ILL policies and procedures and in compliance with Section 108 of the United States Copyright Act, and (iv) such other uses as may be set forth or referenced in an applicable Order. The Permitted Use for specific Online Tools may vary, and additional and/or different uses may be permitted if and to the extent specified in the applicable Order. The use of the Online Tools can be incorporated into course packs and e-reserves only through the use of Jumpstarts. For purposes of this Agreement, “Jumpstarts” shall be defined as links from Subscriber’s Web pages to virtually any point within an Ovid session.

For pay-per-view (“PPV”) deposit account journal article access, an Authorized User may only retain one print copy of the accessed article. The retained printed copy is for single use only and may not be redistributed for any purpose other than its original use, or if needed as support documentation for an FDA filing or other such use. The original e-format may not be downloaded and/or saved to any tangible medium. Any request other than for the original use would be deemed a separate use occasion and the Authorized User will need to access any additional copy or copies from the PPV-deposit website.
  - 1.15. “**Perpetual Access Basis**” means a perpetual subscription for the applicable Online Tools.
  - 1.16. “**Platform**” means, as applicable, (i) the search and retrieval application software made available to Subscriber through the Ovid online platform and any modifications, enhancements, updates, upgrades or new releases to the foregoing (the “**Ovid Platform**”); or (ii) the third party platforms made available to Subscriber to access the Online Tools and any modifications, enhancements, updates, upgrades or new releases to the foregoing (“**Other Platforms**”); provided however, that certain enhancements to the software and platforms described in (i) and (ii) may constitute separate and distinct tools for which Ovid reserves the right to charge an additional fee.
  - 1.17. “**Subscription Basis**” means a subscription to the applicable Online Tools for a defined term and designated on the applicable Order as “Subscription Basis”.
  - 1.18. “**Subscription Fee**” means the fee for access to the Online Tools and the Platforms, as specified in the applicable Orders, including fees for Perpetual Access Basis Online Tools and fees for Subscription Basis Online Tools.
  - 1.19. “**Subscription Term**” means one (1) year from the date of initial access to the applicable Online Tools, unless otherwise specified in the applicable Order.
-

## 2. SUBSCRIPTION AND ACCESS.

- 2.1. **SUBSCRIPTION TO ONLINE TOOLS.** For the Online Tools set forth in an applicable Order, in consideration of payment of the applicable Subscription Fees, Ovid hereby grants to Subscriber the non-transferable (except as set forth herein), nonexclusive, limited right to allow its Authorized Users to access and use the Online Tools specified in the applicable Order via the applicable Platform (subject to payment of any applicable Subscription Fees for access to such Platform) from or through the Authorized Sites (unless otherwise stated in the applicable Order) for the Permitted Use, subject to the terms and conditions of this Agreement. The foregoing grant is effective (i) for Subscription Basis Online Tools, only during the applicable Subscription Term, and (ii) for Perpetual Access Online Tools, on a perpetual basis.
- 2.2. **ACCESS.** Subscriber may access the Online Tools via the applicable Platforms through (i) one or more identification passwords issued by Ovid; (ii) Internet Protocol address validation; (iii) an Ovid-approved online referral link; or (iv) access code redemption by Authorized Users. Method of access to the applicable Platform may change over time. Ovid reserves the right, in its sole discretion, to alter or change Subscriber's identification passwords, if applicable, as circumstances may warrant, and Ovid will promptly notify Subscriber of the foregoing. If Authorized Users are accessing the Online Tools via Internet Protocol address validation, Subscriber warrants that the Internet Protocol addresses provided by Subscriber to Ovid will allow access to the Online Tools only by Authorized Users and no other users will be provided access through the Internet Protocol addresses. Subscriber may elect to use proxy servers to allow Authorized Users to access the applicable Online Tools remotely through the Authorized Sites. If Subscriber elects to provide such remote access, Subscriber will strictly limit such access only to Authorized Users through a secure method of user verification. Subscriber will immediately notify Ovid if it believes unauthorized access of an Online Tool has occurred.
- 2.3. **UPDATES AND DISCONTINUATION.** Ovid may update, modify, or replace the relevant Online Tools or any component, feature, service (including support) or content therein or related thereto, for any reason at any time and from time to time. Ovid reserves the right to discontinue offering access to any Online Tool. Ovid will use commercially reasonable efforts to provide advance notice of any such discontinuation. If an Online Tool is discontinued during the term of this Agreement, then Ovid will, in its discretion, either: (a) provide Subscriber with a pro-rata refund of pre-paid but unused Subscription Fees for the discontinued Online Tool, or (b) provide Subscriber with access to a tool having substantially similar functionality for the remainder of the term of the applicable Order (which substantially similar tool may be, at Ovid's discretion, an electronic copy of the discontinued Online Tool, subject to Subscriber's payment of a media, fulfillment and/or delivery fee and Subscriber's execution of an additional agreement).
- 2.4. **AUDIT.** Subscriber agrees that Ovid may audit the use of the Online Tools for compliance with this Agreement at any time, upon reasonable notice. If the audit reveals any use of the Online Tools in violation of this Agreement, in addition to any other remedies Ovid may have, either at law or in equity, Subscriber shall reimburse Ovid for all reasonable expenses related to such audit.

## 3. PROPRIETARY RIGHTS AND USE RESTRICTIONS.

- 3.1. **PROPRIETARY RIGHTS.** No provision of this Agreement conveys any ownership interest to Subscriber in or to any of the Online Tools, the Platforms, or any Documentation, in whole or in part, and, except for the express rights granted in this Agreement, all intellectual property rights, including copyright, patent, trademark and trade secret, are retained by Ovid, Ovid affiliates or Information Providers, all rights reserved.
- 3.2. **ADDITIONAL TERMS.** Certain additional terms may apply to the Online Tools subscribed to hereunder. Such additional terms, if any, are set forth in the applicable Order. Information Providers may modify or assign additional terms and conditions, as made available to Subscriber by Ovid, from time to time, that may affect the Authorized Users' use of the Online Tools. If any such changes materially impact Subscriber's rights to use the Online Tools, the Parties will discuss an appropriate remedy in light of the circumstances.
- 3.3. **RESTRICTIONS ON USE.** Subscriber shall ensure that the Online Tools are accessed only by Authorized Users at or through Authorized Sites. Subscriber shall be responsible for all uses of the Online Tools by
-

Authorized Users and the confidentiality and security of the passwords or other methods of authentication issued to Subscriber by Ovid. Subscriber shall ensure that all Authorized Users are aware of the limitations and restrictions on the use of the Online Tools. Subscriber shall not, and shall ensure that its Authorized Users shall not (a) copy or duplicate, in whole or in substantial part, any Online Tools; (b) distribute, transmit, publish, transfer or commercially exploit any Online Tool, in whole or in part; (c) incorporate any part of the Online Tools in printed or electronic course or study packs, unless expressly permitted by the Permitted Use; (d) use the Platforms or Online Tools to provide service bureau, time sharing, or similar services to third parties; (e) reverse engineer, decompile or modify any Online Tool, in whole or in part; (f) use the Platforms, the Online Tools or the information contained therein or results derived therefrom to develop any tools, products or services that could be competitive with the Platforms or any Online Tool or any other tools, products or services provided by Ovid or its affiliates; (g) alter, remove, or otherwise hinder the delivery of any copyright, disclaimer, or other proprietary notice appearing in the Platforms or the Online Tools; or (h) share or transfer any usernames or passwords.

- 3.4. **LEGAL ADVICE.** Ovid does not provide legal advice regarding copyright, fair use, or other aspects of intellectual property rights. Persons contemplating any type of transmission or reproduction of copyrighted material are advised to consult legal counsel.
- 3.5. **REPORTING.** Subscriber shall report any breach of any limitations or restrictions on the use of the Online Tools to Ovid promptly (but in no event later than five (5) business days) after becoming aware of the facts or circumstances constituting such breach. Subscriber agrees to promptly notify Ovid of, and to provide full and prompt cooperation and assistance to Ovid with any investigation of, any Authorized User's violation or potential violation of the terms, conditions, or restrictions referenced in this Agreement.
- 3.6. **ENFORCEMENT OF RIGHTS.** Subscriber hereby grants to Ovid, Ovid's affiliates and/or Information Providers the right to enforce or assert on their own behalf the provisions of this Agreement.

#### 4. **TERM.**

This Agreement will become effective upon the Effective Date and will remain in force, unless earlier terminated in accordance with the terms herein, for the term, indicated in Order hereunder remains in effect. Subscriber may elect to remove an Authorized Institution (as identified in Section III of Annex 2 to this Agreement) from this Agreement before the start of Instalment 2 (i.e., for the 31 December 2024 through 30 December 2025 contract year) or Instalment 3 (i.e., for the 31 December 2025 through 30 December 2026 contract year). Written notice of such election by Subscriber must be provided to Ovid at least thirty (30) days prior to the applicable Instalment year (i.e., on or before 1 December 2024 for Instalment 1 and on or before 1 December 2025 for Instalment 2) (each a "**Non-Renewal Notice**"). Subject to the condition to provide a timely Non-Renewal Notice, in the event Subscriber elects to remove an Authorized Institution from this Agreement, the Subscription Fees applicable to such Authorized Institution will be deducted from the invoice for the applicable Instalment year. If Subscriber elects to remove all Authorized Institutions from this Agreement in accordance with this Section, then this Agreement will terminate at the conclusion of the then current Instalment year.

#### 5. **TERMINATION.**

- 5.1. Ovid may terminate this Agreement immediately upon written notice to Subscriber if Subscriber or any Authorized User materially breaches its obligations under any of the following sections of this Agreement: 2.1, 3.1, 3.3 or 10. Either Party (the "**Non-Breaching Party**") shall have the right to terminate this Agreement and/or any Order (a) if the other Party (the "**Breaching Party**") materially breaches any term of this Agreement and fails to cure such breach to the Non-Breaching Party's reasonable satisfaction within ten (10) days of written notice thereof from the Non-Breaching Party or (b) a Termination Event occurs with respect to the Breaching Party; provided, that the Non-Breaching Party shall have the right to immediately terminate this Agreement and/or any Order in the event of any breach by the Breaching Party that cannot be cured within such ten (10) day cure period. If Subscriber or any Authorized User is in breach of the terms and conditions of this Agreement, Ovid reserves the right to immediately suspend access to the Online Tools for any such breach without notice to Subscriber. In the event that Subscriber fails to cure any such breaches,
-

then Ovid shall be entitled to exercise its termination rights (not subject to further cure rights) under this Agreement. “**Termination Event**” means, with respect to a Party, under the applicable bankruptcy laws or similar laws regarding insolvency or relief of debtors, (1) a trustee, receiver, custodian or similar officer is appointed for a Party’s business or property, (2) a Party seeks to liquidate, wind-up, dissolve, reorganize or otherwise obtain relief from its creditors, or (3) an involuntary proceeding is commenced against a Party and the proceeding is not stayed, discharged or dismissed within 30 days of its commencement. If a Termination Event occurs with respect to Subscriber, Subscriber agrees to use its best efforts to obtain court authorization, if required, to pay any and all fees to Ovid and its affiliates.

- 5.2. Except as set forth below, and subject to the survival provisions in Section 11.10, in the event of any expiration or termination of this Agreement, (a) all rights granted to Subscriber by Ovid hereunder shall immediately terminate and all access to the Online Tools shall immediately cease, and Subscriber shall, and shall cause all Authorized Users to, cease all use of the Online Tools and Subscriber shall return to Ovid or destroy all confidential information provided by Ovid to Subscriber, including all copies of the Online Tools and all portions thereof and (b) all earned and unpaid fees and expenses will become immediately due and payable to Ovid. Termination of this Agreement by Ovid pursuant to Section 5.1 will not require payment of a refund to Subscriber and will not affect (1) Subscriber’s obligation to pay any fees due, or (2) any remedies available to Ovid by law or equity. Any termination, whether or not for breach, will not affect any right, obligation or liability of a Party for the time period prior to termination of this Agreement.
- 5.3. The Subscriber may terminate this Agreement according to the article 90 of the Law on Public Procurement of the Republic of Lithuania only to the extent those statutory provisions apply to this Agreement and Subscriber shall pay Subscription Fees for services rendered through the date of termination. Upon termination of this Agreement according to this Section, Ovid shall provide a pro rata refund of the then remaining paid Subscription Fees for the then current, unexpired Instalment period of this Agreement.
- 5.4. The Subscriber may terminate this Agreement in the case of lack of funding or merger or closure of any Authorised Institution by serving written notice to Ovid. The termination will become effective thirty days after the receipt of the written notice unless later term has been specified in the notice. In this case, the Subscriber shall pay only the Subscription Fees then due as of the effective date of the termination.
- 5.5. The Subscriber may terminate this Agreement if Ovid does not submit an invoice pursuant to Section 6.1 without any further obligation to either party.
- 5.6. The Subscriber may terminate this Agreement if the international sanctions are applied to OVID according to the Law on International Sanctions of the Republic of Lithuania (e.g. Article 5 k of the Council Regulation (EU) No 833/2014 of 31 July 2014 concerning restrictive measures in view of Russia’s actions destabilising the situation in Ukraine, as amended by Council Regulation (EU) No 2022/576 of 8 April 2022, etc.).

## 6. FEES.

- 6.1. **SUBSCRIPTION FEES.** Subscriber shall pay the Subscription Fees within sixty (60) days of the date of the applicable invoice. Any amounts owed by Subscriber that are not paid when due shall be subject to late fees at a rate of the lesser of: (a) 1.5% per month and (b) the highest rate permissible under applicable law. Failure to pay all Subscription Fees and applicable taxes within such sixty (60) day period shall constitute a material breach of this Agreement by Subscriber, and Ovid reserves the right to exercise its either its termination or suspension right set forth in Section 5.1 upon any such material breach for non-payment. Subscriber acknowledges and agrees that Ovid’s only preferred payment methods are via Electronic Funds Transfer (EFT) or via Automated Clearing House (ACH) transfers, and Ovid reserves the right to charge Subscriber additional processing fees for any payments made by credit card or any method other than EFT or ACH payment. No later than by 8 December 2023 Ovid shall issue to the LMBA the first invoice in the amount indicated in Item 3, Annex 1 (THE TENDER) payable for Instalment 1 (i.e., the 31 December 2024 through 30 December 2024 contract year). The invoice described in the foregoing sentence and all subsequent invoices issued to the LMBA under this Agreement shall be sent the following email address: [lmba@lmba.lt](mailto:lmba@lmba.lt). If the Supplier fails to timely issue initial invoice (i.e., the invoice due to the LMBA no later than 8 December 2023) to LMBA in accordance with this Section, it shall be considered that the Supplier has
-

refused to provide the Online Tools and therefore it shall lose its right to receive the applicable Subscription Fees and the Agreement shall terminate on 8 December 2023. In such case, the Supplier shall lose its right to the reimbursement of the applicable Subscription Fees. The Supplier shall submit other invoices to the LMBA by the dates agreed between the parties by email. If Supplier fails to timely issue an invoice in accordance with this Section, it shall be considered that the Supplier has refused to provide the Online Tools for that particular Instalment year and the Agreement shall terminate on the last day of the then current Instalment year. In such case, the Supplier shall lose its right to the reimbursement of the applicable Subscription Fees.

- 6.2. **ADJUSTMENT FOR CHANGE.** The conditions of the Agreement may be amended according to the article 89 of the Law on Public Procurement of the Republic of Lithuania. No later than thirty (30) days following any changes with respect to the information supplied by Subscriber in any Order, Subscriber shall update the information contained in the applicable Order by notice of such changes to Ovid, including, without limitation, any mergers or acquisitions, or any additional facilities opened or acquired that should be listed as Authorized Sites. In the event that the change results in a change in fees, the Subscription Fees shall be adjusted in accordance with Ovid's then-current pricing and agreed by both parties in writing. In the event that Subscriber fails to provide such updated information, Ovid reserves the right to charge Subscriber additional fees to cover any period of underpayment by Subscriber.

## 7. PRIVACY/HIPAA

- 7.1. Ovid does not collect any individually identifiable health information (including, but not limited to, protected health information) from Subscriber. Ovid is not a covered entity or business associate under the Health Insurance Portability and Accountability Act of 1996 (Public Law 104-19), as amended.
- 7.2. To the extent that Ovid Processes Personal Data to which Data Protection Laws apply (as such terms are defined in the Data Protection Annex) when performing its obligations under this Agreement, the terms displayed at <https://www.wolterskluwer.com/en/solutions/ovid/data-protection-annex> or any successor URL from time to time (the "Data Protection Annex") applies to such Processing and is incorporated into this Agreement. Ovid may, in its sole discretion, amend or replace the Data Protection Annex at any time without notice to Subscriber or its Authorized Users and Subscriber should review the terms of the latest Data Protection Annex that applies to this Agreement at regular intervals.
- 7.3. Ovid reserves the right to track and collect for its internal purposes personal information about Authorized Users of Ovid, including without limitation, the URL the Authorized User has come from (whether this URL is on its website or not), the URL the Authorized User goes to next (whether this URL is on its website or not), the internet browser being used, the type of operating system used, the Authorized User's location, and the Authorized User's IP address. An Authorized User's IP address may be used for system administration purposes and to track an Authorized User's session, in order to give Ovid an understanding as to which parts of the Online Tools Authorized Users are visiting. Ovid may use such information for purposes including but not limited to improving the content of the Online Tools, marketing, advertising, reports to Subscriber, or research. Ovid may send information and notices of new services to registered Authorized Users. Ovid reserves the right to release current or past user information, whether or not the information identifies a particular person, internally within Ovid or to third parties for limited purposes in the event Ovid believes that the Online Tools are being used in violation of this Agreement or to commit unlawful acts, and/or if Ovid is required to disclose information to comply with applicable laws or regulations, or with a court or administrative order. Except as stated in this paragraph, Ovid will not share with unaffiliated third parties information specific to Authorized Users or share information regarding specific IP addresses. Ovid is, however, free to disclose aggregate non-personal information to third parties.

## 8. LIMITED WARRANTIES AND LIMITED LIABILITIES.

- 8.1. THE ONLINE TOOLS, THE PLATFORMS, THE DOCUMENTATION, AND ANY SUPPORT OR SERVICES PROVIDED HEREUNDER ARE FURNISHED BY OVID, ITS AFFILIATES AND LICENSORS AND ACCEPTED BY SUBSCRIBER "AS IS" AND WITHOUT ANY WARRANTY WHATSOEVER, EITHER EXPRESS OR IMPLIED. OVID, ITS AFFILIATES AND LICENSORS MAKE
-

NO REPRESENTATIONS OR WARRANTIES WITH RESPECT TO THE FOREGOING, AND OVID, ITS AFFILIATES AND LICENSORS DISCLAIM ALL REPRESENTATIONS AND WARRANTIES OF ANY KIND OR NATURE, EXPRESS OR IMPLIED, ARISING OUT OF OR RELATED TO THIS AGREEMENT, THE ONLINE TOOLS, THE PLATFORMS, THE DOCUMENTATION, ANY SUPPORT OR SERVICES OR THE RESULTS DERIVED THEREFROM, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES REGARDING ACCURACY, QUALITY, CORRECTNESS, COMPLETENESS, COMPREHENSIVENESS, CURRENCY, SUITABILITY, SYSTEM AVAILABILITY, COMPATIBILITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, NON-INFRINGEMENT, OR OTHERWISE (IRRESPECTIVE OF ANY COURSE OF DEALING OR PERFORMANCE, CUSTOM OR USAGE OF TRADE). OVID DOES NOT WARRANT THAT THE PLATFORMS OR THE ONLINE TOOLS OR ANY COMPONENT THEREOF WILL BE UNINTERRUPTED, THAT ITS USE OR OPERATION WILL BE ERROR OR DEFECT FREE, THAT THE PLATFORMS OR THE ONLINE TOOLS OR ANY COMPONENT THEREOF WILL ALWAYS BE ACCESSIBLE OR AVAILABLE, OR THAT ALL DEFECTS IN THE PLATFORMS OR THE ONLINE TOOLS WILL BE CORRECTED. SUBSCRIBER WILL BE SOLELY RESPONSIBLE FOR THE SELECTION, USE AND SUITABILITY OF THE ONLINE TOOLS AND OVID WILL HAVE NO LIABILITY THEREFOR. IN ADDITION, SUBSCRIBER ACKNOWLEDGES THAT ACCESS TO THE PLATFORMS AND THE ONLINE TOOLS MAY BE SUBJECT TO LIMITATIONS, DELAYS, LATENCY ISSUES AND OTHER PROBLEMS INHERENT IN THE USE OF THE INTERNET AND ELECTRONIC COMMUNICATIONS, AND THAT OVID, ITS AFFILIATES AND ITS LICENSORS ARE NOT RESPONSIBLE FOR ANY DELAYS, DELIVERY FAILURES, OR OTHER DAMAGE RESULTING FROM SUCH PROBLEMS. NO OVID EMPLOYEE OR AGENT IS AUTHORIZED TO MAKE ANY STATEMENT THAT ADDS TO OR AMENDS THE WARRANTIES OR LIMITATIONS CONTAINED IN THIS AGREEMENT.

- 8.2. THE ONLINE TOOLS ARE NO SUBSTITUTE FOR INDIVIDUAL PATIENT ASSESSMENT BASED UPON AN AUTHORIZED USER'S EXAMINATION OF EACH PATIENT. WHILE CERTAIN ONLINE TOOLS MAY DESCRIBE VARIOUS BASIC PRINCIPLES OF DIAGNOSIS AND THERAPY, SUCH ONLINE TOOLS SHOULD BE USED AS GENERAL MEDICAL REFERENCE MATERIALS TO ASSIST THE AUTHORIZED USER IN REACHING DIAGNOSTIC AND TREATMENT DECISIONS. SUBSCRIBER AND EACH AUTHORIZED USER SHOULD EXERCISE ITS OWN INDEPENDENT PROFESSIONAL AND CLINICAL JUDGMENT, TAKING INTO ACCOUNT INFORMATION ABOUT PARTICULAR INDIVIDUAL PATIENTS THAT CANNOT BE ASCERTAINED OR TAKEN INTO ACCOUNT AS A PART OF NECESSARILY GENERIC OR SUMMARY ONLINE TOOLS. GIVEN CONTINUOUS, RAPID ADVANCES AND CHANGES IN MEDICAL SCIENCE AND HEALTH INFORMATION, SUBSCRIBER AND EACH AUTHORIZED USER SHOULD CONSULT A VARIETY OF SOURCES WHEN PRESCRIBING MEDICATION, INCLUDING THE MANUFACTURER'S "PACKAGE INSERT". THE ABSENCE OF A WARNING FOR A GIVEN DRUG OR DRUG COMBINATION SHOULD NOT BE CONSTRUED TO INDICATE THAT THE DRUG OR DRUG COMBINATION IS SAFE, APPROPRIATE OR EFFECTIVE IN ANY GIVEN PATIENT. SUBSCRIBER ACKNOWLEDGES THAT THE PROFESSIONAL DUTY TO THE PATIENT IN PROVIDING HEALTHCARE SERVICES LIES SOLELY WITH THE HEALTHCARE PROFESSIONAL PROVIDING PATIENT CARE SERVICES. SUBSCRIBER AND THE AUTHORIZED USERS ARE SOLELY RESPONSIBLE FOR THE USE OF ANY ONLINE TOOLS, AND SUBSCRIBER'S AUTHORIZED USERS ARE RESPONSIBLE FOR INDEPENDENTLY REACHING ANY MEDICAL JUDGMENT. TO THE MAXIMUM EXTENT PERMITTED UNDER APPLICABLE LAW, NO RESPONSIBILITY IS ASSUMED BY OVID, ITS AFFILIATES OR LICENSORS FOR ANY INJURY AND/OR DAMAGE TO PERSONS OR PROPERTY, AS A MATTER OF PRODUCTS LIABILITY, NEGLIGENCE LAW OR OTHERWISE, OR FROM ANY REFERENCE TO OR USE BY SUBSCRIBER (OR ANY OF ITS HEALTHCARE PROFESSIONALS, INCLUDING THE AUTHORIZED USERS) OF ANY OF THE ONLINE TOOLS.

## 9. DAMAGES EXCLUSION AND LIMITATIONS OF LIABILITY.

- 9.1. DAMAGES EXCLUSION. IN NO EVENT SHALL OVID, ITS AFFILIATES OR LICENSORS, OR ANY OF ITS OR THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES, DISTRIBUTORS,
-

SUBCONTRACTORS, SUPPLIERS OR AGENTS, HAVE ANY LIABILITY WHATSOEVER (A) (I) FOR BUSINESS INTERRUPTION, LOST PROFITS, LOST REVENUES, LOST BUSINESS OPPORTUNITIES, LOST SALES, LOST GOODWILL, OR EXEMPLARY, PUNITIVE, SPECIAL, INCIDENTAL, INDIRECT, CONSEQUENTIAL OR SIMILAR DAMAGES, OR (II) FOR ANY OTHER LIABILITIES ARISING FROM ANY CLAIMS, DAMAGES, FINES, COSTS, OR EXPENSES, INCLUDING THOSE RELATED TO LOSS, UNAVAILABILITY, CORRUPTION, DISCLOSURE, OR MISUSE OF DATA, EACH OF WHICH IS HEREBY EXCLUDED BY AGREEMENT OF THE PARTIES, REGARDLESS OF WHETHER SUCH DAMAGES WERE FORESEEABLE OR WHETHER A PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES; OR (B) FOR ANY OTHER LIABILITIES ARISING FROM ANY CLAIMS, DAMAGES, FINES, COSTS, OR EXPENSES, INCLUDING THOSE RELATED TO LOSS, UNAVAILABILITY, CORRUPTION, DISCLOSURE, OR MISUSE OF DATA (INCLUDING THOSE RELATING TO OR ARISING FROM A PERSONAL DATA BREACH).

9.2. LIMITATIONS OF LIABILITY. THE TOTAL LIABILITY OF OVID, ITS AFFILIATES AND LICENSORS, OR ANY OF ITS OR THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES, DISTRIBUTORS, SUBCONTRACTORS, SUPPLIERS OR AGENTS ARISING OUT OF OR IN RELATION TO THIS AGREEMENT, THE ONLINE TOOLS AND ANY OTHER CAUSE WHATSOEVER, SHALL NOT EXCEED, IN THE AGGREGATE FOR ANY AND ALL CLAIMS UNDER OR IN RELATION TO THIS AGREEMENT, THE TOTAL FEES PAID BY SUBSCRIBER TO OVID FOR THE AFFECTED SERVICE OR ONLINE TOOL IN THE TWELVE-MONTH PERIOD PRECEDING THE DATE ON WHICH THE FIRST CLAIM OR CAUSE OF ACTION AROSE.

9.3. Bargained for Exchange: Breadth of Claims and Disclaimers. The allocations of liability in this Section represent the agreed, bargained-for understanding of the Parties and Ovid's compensation hereunder reflects such allocations. THE LIMITATIONS OF LIABILITY AND TYPES OF CLAIMS HEREBY LIMITED AND DISCLAIMED SHALL APPLY TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, AND ARE INTENDED BY THE PARTIES TO APPLY REGARDLESS OF THE FORM OF THE CLAIM OR ACTION (WHETHER BASED IN CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER TORT, STATUTE OR OTHERWISE), AND REGARDLESS OF WHETHER ANY LIMITED REMEDY PROVIDED FOR IN THIS AGREEMENT FAILS OF ITS ESSENTIAL PURPOSE.

9.4. Limitations Period. Any claim or cause of action arising under or otherwise relating to this Agreement, the Online Tools or other subject matter hereof or thereof must be commenced within one year from the date such claim or cause of action first arose.

10. **CONFIDENTIALITY.** Subscriber acknowledges that the Online Tools and the Platforms are the proprietary property of Ovid, its affiliates and the Information Providers, and that the processes and methodology used in producing the Online Tools and the Platforms are valuable trade secrets. Subscriber shall protect the confidentiality thereof with at least the same level of efforts that it employs to protect the confidentiality of its own proprietary and confidential information of like importance and in any event, by reasonable means. Subscriber shall not disclose the terms of this Agreement, except as required by law. This provision shall survive the expiration or earlier termination of this Agreement. For avoidance of doubt, this clause is not applicable for the publication of the Agreement and the Order on Lithuanian Central Public Procurement Information System by the Subscriber.

## 11. MISCELLANEOUS.

11.1. **AFFILIATES OF OVID.** The applicable Ovid entity for purposes of this Agreement shall be determined by Subscriber's principal place of business: (i) in Andorra, Belgium, Cyprus, Greece, Iran, Israel, Luxembourg, Malta, the Netherlands, San Marino, Turkey or the Vatican City: Ovid Technologies BV; (ii) in the Aland Islands, Albania, Armenia, Austria, Azerbaijan, Belarus, Bosnia Herzegovina, Bulgaria, Croatia, the Czech Republic, Denmark, Estonia, Faroe Islands, Finland, Georgia, Germany, Greenland, Hungary, Iceland, Kazakhstan, Kosovo, Kyrgyzstan, Latvia, Liechtenstein, Lithuania, Macedonia, Moldova, Montenegro, Norway, Poland, Romania, Russia, Serbia, the Slovak Republic, Slovenia, Svalbard & Jan Mayen, Sweden, Switzerland, Tajikistan, Turkmenistan, Ukraine, or Uzbekistan: Ovid Technologies GmbH;

---

(iii) in Algeria, France, French Guiana, French Polynesia, French Southern Territory, Guadeloupe, Martinique, Monaco, Morocco, New Caledonia, Reunion, Saint Barthélemy, or Tunisia: Ovid Technologies Sarl; (iv) in Portugal or Spain: Ovid Technologies SL; (v) in Afghanistan, Benin, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoro Islands, Congo, Congo Democratic Republic, Djibouti, Egypt, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Guinea, Guinea-Bissau, Iran, Iraq, Italy, the Ivory Coast, Jordan, Lebanon, Liberia, Libya, Malawi, Mali, Mauritania, Mayotte, Niger, Palestine, Rwanda, Sao Tome and Principe, Senegal, Sierra Leone, Somalia, Sudan, Syria, Togo, Western Sahara, Yemen, or Zimbabwe: Ovid Technologies SRL; or (vi) in Angola, Bahrain, Botswana, England, Ghana, Gibraltar, Guernsey, Ireland, Jersey, Kenya, Kuwait, Lesotho, Madagascar, Maldives, Mauritius, Mozambique, Namibia, Nigeria, Northern Ireland, Oman, Qatar, Saudi Arabia, Scotland, Seychelles, South Africa, Swaziland, Tanzania, Uganda, United Arab Emirates, Wales, or Zambia: Wolters Kluwer Health (Medical Research) Ltd. If none of the foregoing is applicable, then the Ovid entity hereunder shall be Ovid Technologies, Inc.

- 11.2. GOVERNING LAW; LANGUAGE OF AGREEMENT.** This Agreement, and any disputes arising out of or related hereto, is governed by and shall be governed by and enforced in accordance with the laws of the State of New York, including its statutes of limitations, without regard to any law or statutory provision that would require or permit the application of another jurisdiction's substantive law, except for Sections 5.3, 6.2, and 11.8, for which the parties agree that the Law on Public Procurement of the Republic of Lithuania applies. The Parties agree that the United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement. Unless otherwise agreed in writing by the Parties, this Agreement and all related documents shall be drawn up in English. Any translations of this Agreement into any other language shall have no effect. All proceedings related to this Agreement shall be conducted in the English language.
- 11.3. DISPUTE RESOLUTION METHOD AND VENUE.** The Parties agree that any dispute arising hereunder shall be submitted for dispute resolution in the method and venue determined by Subscriber's principal place of business, as specified in the Order, as follows: (a) in the United States, disputes shall be submitted to a state or federal court sitting in New York, NY; (b) in Canada, disputes shall be submitted to the federal and provincial courts sitting in Toronto, Ontario; (c) in the Americas, except Canada and the United States, disputes shall be submitted to arbitration in New York, New York, U.S.A., under the rules of the American Arbitration Association; (d) in Europe, the Middle East and Africa, disputes shall be submitted to arbitration in London, England, under the Arbitration Rules of the London Court of International Arbitration; (e) in Asia Pacific, disputes shall be submitted to arbitration in Sydney (NSW), Australia, under the rules of the Australian Commercial Disputes Centre Ltd. Nothing herein shall be deemed to limit or otherwise affect either Party's right to seek immediate equitable (including injunctive) relief for alleged violations of the Party's intellectual property rights or interests.
- 11.4. DISPUTE RESOLUTION PROCEDURES FOR ARBITRATION.** The Parties agree that the following procedures shall apply to any disputes under this Agreement to which arbitration applies as set forth in this Agreement. Arbitration shall be conducted before a single arbitrator, unless the amount in dispute exceeds the equivalent of US\$250,000, to be jointly selected and if the Parties cannot agree on such single arbitrator within a period of 30 days after an arbitration proceeding has commenced, then the single arbitrator will be selected in accordance with the rules of the applicable arbitral body for the relevant jurisdictions set forth in Section 11.3 above. If the amount in dispute exceeds the equivalent of US\$250,000, it shall be decided by a panel of three arbitrators, one to be selected by each Party and the third to be jointly selected by the two Party-appointed arbitrators. The arbitrators must have experience with and knowledge of intellectual property transactions and have been admitted to the practice of law for at least ten years. The language of the arbitral proceedings shall be in English. Under no circumstances are the arbitrators authorized to make awards contrary to the damages exclusions, liability limitations, remedial and other provisions of this Agreement. The arbitration award shall be final and binding on the Parties. The arbitrators shall be authorized to award costs and attorney's fees or to allocate them between the Parties. Any court with jurisdiction shall be entitled to enforce the agreement of the Parties to arbitrate their disputes and enter judgment on any arbitral award hereunder.
- 11.5. ENTIRE AGREEMENT.** This Agreement, user restrictions and other notices concerning the Online Tools, the Platforms or the Documentation as provided from time to time by Ovid, the terms and conditions for
-

Online Tools available at Ovid's websites, all Orders executed between the Parties, any schedules and exhibits to this Agreement, and any other documents referenced herein collectively constitute the entire agreement between the Parties and supersede and extinguish all prior and contemporaneous agreements, negotiations, understandings, representations, warranties, proposals and communications, whether oral or written, between the Parties relating to the subject matter of this Agreement. It is expressly agreed that any terms of a purchase order, requisition, work order, request for proposal or other document or record prepared, issued or provided by or on behalf of Subscriber relating to the subject matter of this Agreement is for administrative convenience only and will have no effect in supplementing, varying or superseding any provisions of this Agreement, will be of no force or effect, and will not be binding on the Parties, regardless of any acknowledgement thereof by Ovid.

- 11.6. **PRECEDENCE.** In the event of any inconsistency or conflict between the terms and conditions of this Agreement and any Order, schedule, exhibit or other attachment, the order of precedence shall be as follows: first, the Order; then the body of this Agreement; then any applicable schedules or exhibits to this Agreement; then any terms or conditions for the Online Tools available at Ovid's websites.
  - 11.7. **NO CONSTRUCTION AGAINST DRAFTER.** Each of the Parties acknowledges that it has had the opportunity to be represented by legal counsel prior to entering into this Agreement, including any Order or any other document hereunder. As a consequence, in construing this Agreement, including any Order or any other document hereunder, no provision hereof shall be construed in favor of one Party on the ground that such provision was drafted by the other Party.
  - 11.8. **AMENDMENT.** This Agreement may not be modified or amended except by a writing signed by both Parties or in accordance with the provisions set forth in Section 3.2 of this Agreement. The parties acknowledge that any amendments to this Agreement shall be subject to the requirements set forth in Article 89 of the Law on Public Procurement of the Republic of Lithuania.
  - 11.9. **WAIVER.** No waiver by a Party of a breach or the failure by a Party to claim a breach of any provision of this Agreement shall constitute a waiver of any subsequent breach of the same or any other provision of this Agreement, and no waiver shall be effective unless made in writing and signed by an authorized representative of the waiving Party.
  - 11.10. **SEVERABILITY.** In the event that any provision of this Agreement is held to be illegal, or otherwise unenforceable, such provision will be severed, stricken and replaced with a legal and enforceable provision that most closely reflects the intent of the Parties with respect thereto and the remainder of this Agreement shall continue in full force and effect.
  - 11.11. **SURVIVAL.** Any terms or conditions of this Agreement that, by their express terms extend beyond termination or expiration of this Agreement or that by their nature shall so extend, shall survive and continue in full force and effect after any termination or expiration of this Agreement. Without limiting the generality of the foregoing, the obligations and rights of the Parties pursuant to Sections 3, 5.2, 6.1, 7, 8, 9, 10, and 11, and any other provisions herein that protect the proprietary rights of Ovid and the Information Providers shall survive the termination or expiration of this Agreement.
  - 11.12. **ASSIGNMENT.** Subscriber shall not assign this Agreement nor delegate any of its duties, in whole or in part, without the prior express written consent of Ovid. In no event shall Ovid's consent be construed as discharging or releasing Subscriber any way from the performance of its obligations under this Agreement. Ovid may assign this Agreement to any affiliate or successor of Ovid and may delegate its duties, in whole or in part, in each case without any consent of Subscriber. An assignee of either Party authorized hereunder shall be bound by the terms of this Agreement and shall have all of the rights and obligations of the assigning Party set forth in this Agreement. If any assignee refuses to be bound by all of the terms and obligations of this Agreement or if Subscriber attempts to assign this Agreement or any of its rights or obligations under this Agreement in breach of this Section 11.12, then such assignment shall be null and void and of no force or effect.
-

- 11.13. **JURY TRIAL WAIVER. TO THE EXTENT PERMITTED BY APPLICABLE LAW, EACH PARTY KNOWINGLY, VOLUNTARILY AND UNCONDITIONALLY WAIVES ITS RIGHT TO A JURY TRIAL FOR ANY DISPUTE IN CONNECTION WITH THIS AGREEMENT.**
- 11.14. **NO THIRD-PARTY BENEFICIARY.** Except for Ovid’s suppliers and licensors, and except as provided in Section 3.6, no third party is intended to be nor will be a third-party beneficiary of any provision under this Agreement, and Ovid and Subscriber will be the only parties entitled to enforce the rights and terms set out in this Agreement.
- 11.15. **FORCE MAJEURE.** Except for a Party’s obligation to pay fees that are due, neither Party will be liable for any failure or delay in performance under this Agreement for causes beyond that Party’s reasonable control and occurring without that Party’s fault, including but not limited to, acts of God, acts of government, flood, fire, civil unrest or war, acts of terror, declaration of a pandemic by the World Health Organization, labor strikes (other than those involving the Party’s employees), computer attacks or malicious acts, such as attacks on or through the Internet, or failures of service of any telecommunications or Internet service carriers or providers (a “**Force Majeure Event**”). The Party affected by the Force Majeure Event will (a) use reasonable efforts after the start of the Force Majeure Event to notify the other Party in writing of the Force Majeure Event including the likely or potential duration, if known, and the effect on its ability to perform any of its obligations under the Agreement] and (b) use reasonable means to mitigate the effect of the Force Majeure Event on the performance of its obligations. Dates by which performance obligations are scheduled to be met will be extended for a period of time equal to the time lost due to the Force Majeure. For the avoidance of doubt, this Section to the extent applicable will operate to relieve Ovid of the fine provided for in Section 5 of Annex II to this Agreement.
- 11.16. **HEADINGS.** All headings are for reference purposes only and shall not affect the meaning or interpretation of any provisions of this Agreement.
- 11.17. **NOTICES.** All notices, consents or other communications referred to in this Agreement will be in writing and will be conveyed to the other Party by First Class Mail, return receipt requested, or overnight courier (e.g., FedEx, UPS, etc.) to Ovid at 28 Liberty Street, New York, NY 10005, Attn: Legal Department or to Subscriber at the address set forth in the Order. Service of such notice, consent or other communication hereunder will be effective when the return receipt is received or upon proof of delivery from the courier.
- 11.18. **COUNTERPARTS.** This Agreement may be signed in counterparts, all of which upon execution and delivery shall be considered originals and together shall constitute one agreement. Signed facsimile or portable document format (PDF) copies of this Agreement will legally bind the Parties to the same extent as original documents.

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed and hereby represent and warrant that their respective signatory below has been and is, on the date of this Agreement, duly authorized by all necessary corporate action to execute this Agreement.

**OVID TECHNOLOGIES, INC.**

**LITHUANIAN RESEARCH LIBRARY CONSORTIUM**

DocuSigned by

By: \_\_\_\_\_ Digitally signed


By: \_\_\_\_\_

Name: \_\_\_\_\_  
Date: 2023.11.23

Name: \_\_\_\_\_

Title: \_\_\_\_\_ 09:50:38 +01'00'

Title: \_President\_\_\_\_\_



ORDER

THE TENDER

FOR THE SERVICES OF SUBSCRIPTION TO THE ONLINE RESEARCH DATABASE

LIPPINCOTT WILLIAMS & WILKINS JOURNALS

---

ANNEX 1  
to the Contract Documents  
THE FORM OF THE TENDER

To the Lithuanian Research Library Consortium

**TENDER FOR THE SERVICES OF SUBSCRIPTION TO THE ONLINE  
RESEARCH DATABASE  
LIPPINCOTT WILLIAMS & WILKINS JOURNALS  
12<sup>TH</sup> OF OCTOBER 2023**

(Date)

Berlin

(Place)

The Supplier's name <i>If a group of Suppliers is submitting the Tender, the names of all members of the group must be listed</i>	OVID Technologies GmbH
The name, surname and position of the person responsible for the availability of the access	
Phone	+48 662 005 789
E-mail	@wolterskluwer.com

1. By this Tender we confirm that we accept all procurement conditions laid down by the Contract Documents of the negotiated procedure without prior publication.

2. We would like to propose the following services indicated in the Contract Documents:

**2024 m.**

No	Type of the service	Price in EUR, VAT exclusive	Price in EUR, VAT inclusive <sup>1</sup>
1.	The services of subscription to the online research database <i>Lippincott Williams &amp; Wilkins journals</i> for the Authorised Users of the LMBA Authorised Institutions from 31 December 2023 till 30 December 2024		
1.1	Lithuanian University of Health Sciences	25,146.00	26,403.30
1.2	Vilnius University	72,035.00	75,636.75
	<b>TOTAL for 2024:</b>	97,181.00	102,040.05

<sup>1</sup> The Supplier shall indicate the price, VAT inclusive, with regard to the VAT rate indicated under the Table. When the VAT rate is 0, the price excluding VAT shall correspond to the price including VAT.

**2025 m.**

ENo	Type of the service	Price in EUR, VAT exclusive	Price in EUR, VAT inclusive <sup>2</sup>
1.	The services of subscription to the online research database <i>Lippincott Williams &amp; Wilkins journals</i> for the Authorised Users of the LMBA Authorised Institutions from 31 December 2024 till 30 December 2025		
1.1	Lithuanian University of Health Sciences	26,781.00	28,120.05
1.2	Vilnius University	76,717.00	80,552.85
	<b>TOTAL for 2025:</b>	103,498.00	108,672.90

**2026 m.**

ENo	Type of the service	Price in EUR, VAT exclusive	Price in EUR, VAT inclusive <sup>3</sup>
1.	The services of subscription to the online research database <i>Lippincott Williams &amp; Wilkins journals</i> for the Authorised Users of the LMBA Authorised Institutions from 31 December 2025 till 30 December 2026		
1.1	Lithuanian University of Health Sciences	28,521.00	29,947.05
1.2	Vilnius University	81,704.00	85,789.20
	<b>TOTAL for 2026:</b>	110,225.00	115,736.25
	<b>TOTAL for 2024-2026</b>	310,904.00	326,449.20

Total price of the Tender, VAT inclusive – 326,449.20 EUR.

This amount includes all costs and all taxes, as well as the VAT which is equal 15,545.20 EUR. The VAT rate is 5 %.

3. The Supplier shall issue the Invoices for the below indicated amounts payable for the following terms:

3.1. Instalment 1 – from 31 December 2023 till 30 December 2024 – 102,040.05 EUR (VAT inclusive),

3.2. Instalment 2 – from 31 December 2024 till 30 December 2025 – 108,672.90 EUR (VAT inclusive),

<sup>2</sup> The Supplier shall indicate the price, VAT inclusive, with regard to the VAT rate indicated under the Table. When the VAT rate is 0, the price excluding VAT shall correspond to the price including VAT.

<sup>3</sup> The Supplier shall indicate the price, VAT inclusive, with regard to the VAT rate indicated under the Table. When the VAT rate is 0, the price excluding VAT shall correspond to the price including VAT.

3.3. Instalment 3 – from 31 December 2025 till 30 December 2026 – 115,736.25 EUR (VAT inclusive)

4. We confirm that the content and scope of the proposed services comply with the *Requirements for the scope of the services* set forth in Annex 2 Part II of the Contract Documents.

5. We offer to provide the services for the institutions listed in Annex 2, Part III *Authorised Institutions* of the Contract Documents.

6. The Tender shall be valid for the time period set forth in the Contract Documents.

7. The following documents are enclosed to the Tender:

No.	Type of the document	Number of pages in the document
1.	Specification of the Procurement Object	6
2.	ESPD	14
3.	The Supplier's Oath Declaration Annex 4	3
4.	The Supplier's Declaration Annex 5	1

8. To perform the Agreement, we intend to invoke the following sub-suppliers  
\_\_\_\_\_ for this part of the Licence Agreement

(name and address)

9. The Tender contains the following confidential information\*:

No.	Title of the submitted document or the part thereof

\* To be completed only in the cases when the confidential information is being submitted.

10. The Supplier shall indicate the data of the following persons:

- the chief executive officer;
- a member of other management or supervisory body or other person (persons) entitled to represent the Supplier or to exercise control over the Supplier, to make decision on its behalf, to conclude a transaction;

• person(s) entitled to draw up and sign the Supplier's financial records;  
and shall submit the documents evidencing that neither of the grounds for rejecting the Supplier are applicable in respect to the person (persons) listed in the below table (if any), namely: the judgement of conviction was not passed and became effective within the past five years and this person does not have the unspent or non-expunged conviction, as stipulated by Item 1, Annex 3 of the Contract Documents.

Name, surname	Position
	Director, Independent Proxy

Director \_\_\_\_\_

(Name, surname, position and signature of the Supplier or its authorised representative)

ANNEX 2  
to the Contract Documents  
THE SPECIFICATION OF THE PROCUREMENT  
OBJECT

**TECHNICAL SPECIFICATION**

**FOR THE SERVICES OF SUBSCRIPTION TO THE ONLINE RESEARCH  
DATABASE  
*LIPPINCOTT WILLIAMS & WILKINS JOURNALS***

*I. Background information*

1. The Lithuanian Research Library Consortium (hereinafter referred to as the LMBA or the Contracting Authority) wishes to procure the access to the Licensed Materials of the research database *Lippincott Williams & Wilkins journals* for the Authorised Users of the LMBA Authorised Institutions listed in *Part III. Authorised Institutions* herein.
2. During the validity period of the Licence Agreement, a contact person of the Contracting Authority on the issues of the Technical Specification, availability of the access and the databases administration shall be \_\_\_\_\_, Manager of Databases:  
E-mail: [\\_\\_\\_\\_\\_@lmba.lt](mailto:_____@lmba.lt); phone: +370 615 87104  
Lithuanian Research Library Consortium  
Saulėtekio ave. 14  
LT-10223 Vilnius  
Lithuania
3. A contact person of the Supplier on the issues related to the availability of the access shall be indicated in the Supplier's Tender. The information about the contact person appointed by the Supplier shall be copied to the Licence Agreement. The contact information of other persons responsible for technical solutions, statistical data and administration can be sent at the e-mail address indicated herein above. If the data of the Supplier's contact person are changed, the Supplier shall provide in writing the updated information during the reasonable time period after the change of the data.

*II. Requirements for the scope of the services*

4. The Authorised Users of the LMBA Authorised Institutions shall have access to the Licensed Materials of the online research database *Lippincott Williams & Wilkins journals*. The list of the titles is provided in Annex A to the Technical Specification *The List of the Titles of the Online Research Database Lippincott Williams & Wilkins journals*.
5. The Authorised Users of the LMBA Authorised Institutions indicated in Part III herein, shall have the online access to the Licensed Materials of the online research database *Lippincott Williams & Wilkins journals* **from 31 December 2023 till 30 December 2026 (with possibility to opt out in case no funding will be available for 2025 and/or 2026)**, 24 hours per day, 7 days per week, including weekends and days-off, except short periods of technical maintenance and repairs service or other unexpected downtime about which, when they are known, the Publisher shall in advance inform the Authorized Users. If an interruption of the access and use of the Licensed Material lasts for more than 5 consecutive days (after the LMBA has notified the Supplier about the lost access), the Supplier shall pay the LMBA a fine equalling to 0.02 percent of the Fee for each delayed day starting

with the sixth delayed day after the notification to the Supplier. No fine will be paid for the accumulating periods of non-continuous interruptions or any interruption caused by any negligence or wilful misconduct by the LMBA or any Authorised Institution or Authorised User.

6. Upon coming into effect of the Licence Agreement, a **Uniform Resource Locator (URL)**, as well as all other information deemed necessary for the availability of the access to this research database *Lippincott Williams & Wilkins journals* shall be sent to the Manager of Databases by the e-mail indicated in Item 2 herein.
7. The Supplier shall make available to the Authorized Institutions COUNTER-compliant usage statistics on at least a quarterly basis.
8. At the request of the Authorized Institutions the Supplier shall make available the Licensed Materials in KBART format.
9. The Supplier should inform the Manager of Databases by the e-mail indicated in Item 2 herein about any changes in the content of the Licenced Materials of the research database *Lippincott Williams & Wilkins journals* immediately.

### III. Authorised Institutions

10. The online access, including the remote access by the Authorised Users, to the Licensed Materials of the online research database *Lippincott Williams & Wilkins journals* shall be given to the 3 simultaneous concurrent Authorised Users via the servers of the Virtual Library of Lithuania (<http://www.lvb.lt/>) through reputable discoverability service partners indexing portals (such as Primo, <https://knowledge.exlibrisgroup.com/primo>), and the IP addresses of 2 (two) Authorised Institutions – members of the LMBA set forth in the below Table:

No.	Institution	FTE	Address	IP addresses
1.	Lithuanian University of Health Sciences	7780	Eivenių g. 6, LT-50162 Kaunas, Lithuania	193.219.37.* 193.219.162.* 193.219.163.* 193.219.180.* 193.219.169.241-245 195.182.67.242
2.	Vilnius University	23181	Universiteto g. 3, LT-01122 Vilnius, Lithuania	158.129.128.0/24 158.129.129.0/24 158.129.132-140.0/24 158.129.144-152.0/24 158.129.154-161.0/24 158.129.162.1-193 158.129.162.194 (VU VPN) 158.129.162.195-254 158.129.164-166.0/24 158.129.168-170.0/24 158.129.172-173.0/24 158.129.180-183.0/24 193.219.42.0/25 193.219.81.0/27 193.219.81.249/30 193.219.82.224/27 193.219.83.0/24 193.219.86.0/24 (Proxy) 193.219.87.0/24 (Proxy)

				193.219.89.0/25 193.219.91.0/25 193.219.94.64/26 193.219.95.128/28 (VU VPN) 193.219.129.128/27 193.219.135.128/29 88.119.140.104 193.219.168.0 – 123 193.219.168.126 – 255 158.129.80-87.*
--	--	--	--	--

11. Any of the IP addresses indicated in Item 10 herein can be adjusted. The Supplier shall be informed about the adjusted IP address by the Manager of Databases by e-mail by specifying the date of the adjustment of the IP addresses and providing for a time period of at least three business days to make the relevant technical modifications for assuring the access to the Licensed Material at the newly provided IP addresses. Should the IP addresses be adjusted prior to concluding the License Agreement, the new valid IP addresses of the Authorised Institutions shall be entered into the Licence Agreement.

ANNEX A

TO THE TECHNICAL SPECIFICATION FOR SERVICES OF SUBSCRIPTION TO THE ONLINE  
RESEARCH DATABASE *LIPPINCOTT WILLIAMS & WILKINS JOURNALS*

**List of the Titles of the Online Research Database *Lippincott Williams & Wilkins journals***

	<b>Title</b>	<b>ISSN</b>	<b>Access from</b>	<b>Access to</b>
1	Anesthesia & Analgesia and A&A Case Reports Bundle	0003-2999**	Vol 36 #1 (1957)	current*
2	Academic Medicine	1040-2446	Vol 75 #1 (2000)	current*
3	Advances in Anatomic Pathology	1072-4109	Vol 8 #1 (2001)	current*
4	Advances in Skin & Wound Care	1527-7941	Vol #1 (2002)	current*
5	AIDS	0269-9370	Vol 11 # 1 (1997)	current*
6	Applied Immunohistochemistry & Molecular Morphology	1062-3345	Vol 4 #1 (1996)	current*
7	American Journal of Clinical Oncology	0277-3732	Vol 19 #1 (1996)	current*
8	American Journal of Dermatopathology, The	0193-1091	Vol 18 #1 (1996)	current*
9	American Journal of Forensic Medicine and Pathology, The	0195-7910	Vol 17 #1 (1996)	current*
10	American Journal of Physical Medicine & Rehabilitation	0894-9115	Vol 75 #1 (1996)	current*
11	American Journal of Surgical Pathology, The	0147-5185	Vol 20 #1 (1996)	current*
12	American Journal of Therapeutics	1075-2765	Vol 8 #1 (2001)	current*
13	Alzheimer Disease & Associated Disorders	0893-0341	Vol 14 #1 (2000)	current*
14	Anesthesiology	0003-3022	Vol 82 #1 (1995)	current*
15	Annals of Plastic Surgery	0148-7043	Vol 46 #1 (2001)	current*
16	Annals of Surgery	0003-4932	Vol 224 #1 (1996)	current*
17	Cardiology in Review	1061-5377	Vol 9 #1 (2001)	current*
18	Coronary Artery Disease	0954-6928	Vol 11 #1 (2000)	current*
19	Critical Care Medicine	0090-3493	Vol 23 #1 (1995)	current*
20	Critical Care Nursing Quarterly	0887-9303	Vol 21 #4 (1999)	current*
21	Circulation	0009-7322	Vol 1 #1 (1950)	current*
22	Clinical Journal of Pain	0749-8047	Vol 12 #1 (1996)	current*
23	Clinical Journal of Sport Medicine	1050-642X	Vol 10 #1 (2000)	current*
24	Cancer Journal, The: The Journal of Principles & Practice of Oncology	1528-9117	Vol 8 #1 (2002)	current*
25	Current Opinion in Allergy and Clinical Immunology	1528-4050	Vol 1 #1(2001)	current*
26	Current Opinion in Anesthesiology	0952-7907	Vol 11 #1 (1998)	current*
27	Current Opinion in Psychiatry	9517367	Vol 1 #1 (1988)	current*
28	Clinical Obstetrics and Gynecology	0009-9201	Vol 39 #1 (1996)	current*
29	Current Opinion in Critical Care	1070-5295	Vol 5 #1 (1999)	current*
30	Current Opinion in Clinical Nutrition and Metabolic Care	1363-1950	Vol 1 #1 (1998)	current*
31	Current Opinion in Cardiology	0268-4705	Vol 14 #1 (1999)	current*
32	Current Opinion in Endocrinology, Diabetes& Obesity	1752-296X	Vol 6 #1 (1999)	current*
33	Current Opinion in Gastroenterology	0267-1379	Vol 15 #1 (1999)	current*
34	Current Opinion in Hematology	1065-6251	Vol 6 #1 (1999)	current*
35	Current Opinion in Infectious Diseases	0951-7375	Vol 11 #1 (1998)	current*
36	Current Opinion in Neurology	1350-7540	Vol 11 #1 (1998)	current*
37	Continuum: Lifelong Learning in Neurology	1080-2371	1993 volumes by topic	current*

	Title	ISSN	Access from	Access to
38	Current Opinion in Obstetrics and Gynecology	1040-872X	Vol 10 #1 (1998)	current*
39	Current Opinion in Otolaryngology & Head and Neck Surgery	1068-9508	Vol 7 #1 (1999)	current*
40	Current Opinion in Oncology	1040-8746	Vol 11 #1 (1999)	current*
41	Current Opinion in Ophthalmology	1040-8738	Vol 10 #1 (1999)	current*
42	Current Opinion in Organ Transplantation	1087-2418	Vol 4 #1 (1999)	current*
43	Current Opinion in Pediatrics	1040-8703	Vol 11 #1 (1999)	current*
44	Current Opinion in Pulmonary Medicine	1078-1641	Vol 5 # 1 (1999)	current*
45	Current Opinion in Rheumatology	1040-8711	Vol 11 #1 (1999)	current*
46	Cornea	0277-3740	Vol 19 #1 (2000)	current*
47	Current Opinion in Supportive and Palliative Care	1751-4258	Vol. 1 #1 (2007)	current*
48	Current Opinion in Urology	0963-0643	Vol 8 #1 (1998)	current*
49	Dimensions of Critical Care Nursing	0730-4625	Vol 20 #1 (2001)	current*
50	Diseases of the Colon & Rectum	0012-3706	Vol 47 #1 (2004)	current*
51	European Journal of Gastroenterology & Hepatology	0954-691X	Vol 13 #1 (2001)	current*
52	Epidemiology	1044-3983	Vol 11 #1 (2000)	current*
53	Exercise and Sport Sciences Reviews	0091-6331	Vol 29 #1 (2001)	current*
54	European Journal of Anaesthesiology	0265-0215	Vol 13 #1(1996)	current*
55	Holistic Nursing Practice	0887-9311	Vol 13 #2 (1999)	current*
56	International Journal of Gynecological Pathology	0277-1691	Vol 19 #1 (2001)	current*
57	International Ophthalmology Clinics	0020-8167	Vol 40 #2 (2000)	current*
58	Journal of Bone and Joint Surgery - American Volume Bundle	0021-9355***	Vol 1 #1 (1889)	current*
59	Journal of Cardiovascular Nursing	0889-4655	Vol 12 #2 (1998)	current*
60	Journal of Cardiovascular Medicine	1558-2027	Vol 7 #1 (2006)	current*
61	Journal of Computer Assisted Tomography	0363-8715	Vol 20 #1 (1996)	current*
62	Journal of Clinical Gastroenterology	0192-0790	Vol 22 #1 (1996)	current*
63	Journal of Cardiovascular Pharmacology	0160-2446	Vol 27 #1 (1996)	current*
64	Journal of Clinical Psychopharmacology	0271-0749	Vol 15 #1 (1995)	current*
65	Journal of Craniofacial Surgery	1049-2275	Vol 12 #1 (2001)	current*
66	Journal of Glaucoma	1057-0829	Vol 10 #1 (2001)	current*
67	Journal of Head Trauma Rehabilitation	0885-9701	Vol 14 #1 (1999)	current*
68	Journal of Hypertension	0263-6352	Vol 15 #1 (1997)	current*
69	Journal of Neurosurgical Anesthesiology	0898-4921	Vol 12 #1 (2000)	current*
70	Journal of Nervous and Mental Disease, The	0022-3018	Vol 184 #1 (1996)	current*
71	Pain	0304-3959	Vol 1 #1 (1975)	current*
72	Journal of Perinatal & Neonatal Nursing	0893-2190	Vol 12 #4 (1999)	current*
73	Journal of Pediatric Gastroenterology and Nutrition	0277-2116	Vol 22 #1 (1996)	current*
74	Journal of Pediatric Hematology/Oncology	1077-4114	Vol 18 #1 (1996)	current*
75	Journal of Pediatric Orthopaedics B	1060-152X	Vol 10 #1 (2001)	current*
76	Journal of Pediatric Orthopaedics	0271-6798	Vol 16 #1 (1996)	current*
77	Journal of Strength and Conditioning Research	1064-8011	Vol 18 #1 (2004)	current*
78	Journal of Trauma and Acute Care Surgery, The	2163-0755	Vol 1 #1 (1961)	current*
79	Journal of Urology	0022-5347	Vol #1 (2015)	current*

	Title	ISSN	Access from	Access to
80	Medical Care	0025-7079	Vol 34 #1 (1996)	current*
81	Medicine & Science in Sports & Exercise	0195-9131	Vol 28 #1 (1996)	current*
82	Neurology and Neurology: Clinical Practice Bundle	0028-3878**	Vol 1 #1 (1951)	current*
83	Neurologist, The	1074-7931	Vol 7 #4 (2001)	current*
84	Obstetrics & Gynecology	0029-7844	Vol 85 #1 (1995)	current*
85	Obstetric Anesthesia Digest	0275-665X	Vol 21 #1 (2001)	current*
86	Obstetrical & Gynecological Survey	0029-7828	Vol 50 #1 (1995)	current*
87	Ophthalmic Plastic and Reconstructive Surgery	0740-9303	Vol 16 #1 (2000)	current*
88	Otology & Neurotology	1531-7129	Vol 22 #1 (2001)	current*
89	International Anesthesiology Clinics	0020-5907	Vol 38 #1 (2000)	current*
90	Pediatric Emergency Care	0749-5161	Vol 16 #1 (2000)	current*
91	Menopause	1072-3714	Vol 7 #6 (2000)	current*
92	Pancreas	0885-3177	Vol 1 #1 (1986)	current*
93	Pediatric Critical Care Medicine	1529-7535	Vol 1 #1 (2000)	current*
94	Pharmacogenetics and Genomics	0960-314X	Vol 15 #1 (2005)	current*
95	Pediatric Infectious Disease Journal, The	0891-3668	Vol 15 #1 (1996)	current*
96	Plastic and Reconstructive Surgery	0032-1052	Vol 97 #1 (1996)	current*
97	JPO: Journal of Prosthetics and Orthotics	1040-8800	Vol 13 #1 (2001)	current*
98	Pediatric Physical Therapy	0898-5669	Vol 12 #1 (2000)	current*
99	Retina	0275-004X	Vol 20 #1 (2000)	current*
100	Shock	1073-2322	Vol 17 #1 (2002)	current*
101	Surgical Laparoscopy, Endoscopy & Percutaneous Techniques	1530-4515	Vol 9 #2 (1999)	current*
102	Southern Medical Journal	0038-4348	Vol 93 #1 (2000)	current*
103	Spine	0362-2436	Vol 21 #1 (1996)	current*
104	Stroke	0039-2499	Vol 1 #1 (1970)	current*
105	Transplantation	0041-1337	Vol 61 #1 (1996)	current*

\*Online access in the *Access to* column marked as current shall mean the access given up to and including the most current issue published by the Publisher during the validity period of the License Agreement.

\*\* A bundle of multiple journals, the ISSN and coverage listed for the main journal only.